Diagnostic performance of 18F-2-fluoro-2-deoxy-D-glucose PET/computerized tomography in identifying bone marrow infiltration in new patients with diffuse large B-cell lymphoma and Hodgkin lymphoma

• Published in: Nuclear medicine communications Vol. 41; no. 3; p. 269
• Main Authors: Kandeel, Ahmed A, Hussein, Mai, Zidan, Lamia, Younis, Jehan, Edesa, Wael, Alsayed, Yasser
• Format: Journal Article
• Language: English
• Published: England 01.03.2020
• Subjects: Adult; Aged; Bone Marrow Neoplasms - diagnostic imaging; Bone Marrow Neoplasms - secondary; Bone Marrow Neoplasms - therapy; Chemoradiotherapy; Female; Fluorodeoxyglucose F18; Hodgkin Disease - diagnostic imaging; Hodgkin Disease - pathology; Hodgkin Disease - therapy; Humans; Ilium - diagnostic imaging; Lymphoma, B-Cell - diagnostic imaging; Lymphoma, B-Cell - pathology; Lymphoma, B-Cell - therapy; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; Sensitivity and Specificity; Young Adult
• ISSN: 1473-5628
• DOI: 10.1097/MNM.0000000000001139

To compare between F-2-fluoro-2-deoxy-D-glucose PET/computerized tomography (F-FDG PET/CT) and routine iliac bone marrow biopsy (BMB) in assessment of bone marrow infiltration (BMI) in Hodgkin lymphoma and diffuse large B-cell lymphoma (DLBCL) patients at initial presentation. A retrospective analysis of 138 patients (50 Hodgkin lymphomas, 88 DLBCLs). The study included 70 males and 68 females with median age of 43 years. All patients underwent F-FDG PET/CT and iliac crest BMB before treatment. Any focal or patchy FDG uptake in the bone marrow, superior-to hepatic uptake was interpreted as abnormal with or without corresponding CT changes. Treatment response was evaluated clinically with each cycle of chemotherapy, radiologically after three cycles and at the end of treatment. The overall diagnostic performance showed significant higher sensitivity of F-FDG PET/CT than that of BMB (73.9 versus 62.5%, P = 0.046), while the specificity was higher in BMB than in F-FDG PET/CT (100% in BMB versus 93.5% in F-FDG PET/CT). In Hodgkin lymphoma, sensitivity, negative predictive value (NPV) and accuracy were significantly higher in F-FDG PET/CT compared with BMB, being 87.5, 94.4 and 96% versus 50, 81 and 84% (P = 0.02, 0.03, 0.04, respectively). However, for DLBCL patients, almost comparable results were found between both tests in terms of sensitivity, NPV and accuracy (66.7, 83.9 and 81.8% versus 68.8, 84.9 and 88.6%, respectively). After PET/CT scan, 12 patients (8.6%) were upstaged to stage IV, eight of them were negative by BMB. F-FDG PET/CT seemed to be an excellent diagnostic test in assessment of BMI at initial assessment and staging of Hodgkin lymphoma and DLBCL patients.